'''Gevotroline''' ('''WY-47,384''') is an [[atypical antipsychotic]] with a [[tricyclic]] [[chemical structure|structure]] which was under development for the treatment of [[schizophrenia]] by [[Wyeth-Ayerst]].<ref name="isbn0-412-46630-9">{{cite book | author = David J. Triggle | title = Dictionary of Pharmacological Agents | publisher = Chapman & Hall/CRC | location = Boca Raton | year = 1996 | pages = | isbn = 0-412-46630-9 | oclc = | doi = | url = https://books.google.com/books?id=Z_mfTTIApVEC&printsec=frontcover#}}</ref><ref name="isbn0-12-040525-3">{{cite book | author = Bristol, James A. | title = Annual Reports in Medicinal Chemistry (Volume 25) | publisher = Academic Press | location = Boston | year = 1990 | pages = | isbn = 0-12-040525-3 | oclc = | doi = | url = https://books.google.com/books?id=NZZbEkldeJAC&lpg=PA2&dq=gevotroline&pg=PA2#v=onepage&q}}</ref><ref name="isbn0-8493-7632-7">{{cite book |author1=Stone, T. W. |author2=Stone, Trevor | title = CNS neurotransmitters and neuromodulators: dopamine | publisher = CRC Press | location = Boca Raton | year = 1996 | pages = | isbn = 0-8493-7632-7 | oclc = | doi = | url = https://books.google.com/books?id=ObG24oxrivEC&lpg=PA187&dq=gevotroline&pg=PA187#v=onepage&q}}</ref> It acts as a balanced, modest [[affinity (pharmacology)|affinity]] [[D2 receptor|D<sub>2</sub>]] and [[5-HT2 receptor|5-HT<sub>2</sub> receptor]] [[receptor antagonist|antagonist]] and also possesses high [[affinity (pharmacology)|affinity]] for the [[sigma receptor]].<ref name="isbn0-12-040525-3" /><ref name="pmid2577720">{{cite journal |vauthors=Snyder SH, Largent BL | title = Receptor mechanisms in antipsychotic drug action: focus on sigma receptors | journal = The Journal of Neuropsychiatry and Clinical Neurosciences | volume = 1 | issue = 1 | pages = 7–15 | year = 1989 | pmid = 2577720 | doi = | url = }}</ref><ref name="pmid1675451">{{cite journal |vauthors=Matheson GK, Guthrie D, Bauer C, Knowles A, White G, Ruston C | title = Sigma receptor ligands alter concentrations of corticosterone in plasma in the rat | journal = Neuropharmacology | volume = 30 | issue = 1 | pages = 79–87 |date=January 1991 | pmid = 1675451 | doi = 10.1016/0028-3908(91)90046-E| url = }}</ref><ref name="pmid1348112">{{cite journal |vauthors=Gudelsky GA, Nash JF | title = Neuroendocrinological and neurochemical effects of sigma ligands | journal = Neuropharmacology | volume = 31 | issue = 2 | pages = 157–62 |date=February 1992 | pmid = 1348112 | doi = 10.1016/0028-3908(92)90026-L| url = }}</ref> It was well-tolerated and showed efficacy in [[clinical trial#Phase II|phase II]] [[clinical trial]]s but was never marketed.<ref name="isbn0-12-040525-3" /><ref name="isbn0-8493-7632-7" />
